CHST14

Across TCGA pan-cancer cohorts, CHST14 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CHST14 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CHST14 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHST14 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where CHST14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.302	0.540	.002	27	view →
LUAD	DFS	Median	II,III,IV	0.791	0.915	.019	17	view →
HNSC	DFS	Tertile	IV	0.529	0.850	.006	8	view →
CCRCC	DFS	Median	III,IV	1.000	0.796	.019	5	view →
LSCC	OS	Quartile	II,III,IV	0.576	1.000	.014	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CHST14–PDAC (DFS)

Open the PDAC breakdown →